Plasma indoleamine 2,3-dioxygenase activity as a potential biomarker for early diagnosis of multidrug-resistant tuberculosis in tuberculosis patients by Shi, Wen et al.
University of Massachusetts Medical School 
eScholarship@UMMS 
Open Access Articles Open Access Publications by UMMS Authors 
2019-05-14 
Plasma indoleamine 2,3-dioxygenase activity as a potential 
biomarker for early diagnosis of multidrug-resistant tuberculosis 
in tuberculosis patients 
Wen Shi 
The First Affiliated Hospital of Nanjing Medical University 
Et al. 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/oapubs 
 Part of the Bacterial Infections and Mycoses Commons, Biological Factors Commons, Diagnosis 
Commons, Enzymes and Coenzymes Commons, Immunology and Infectious Disease Commons, and the 
Therapeutics Commons 
Repository Citation 
Shi W, Wu J, Tan Q, Hu C, Zhang X, Pan H, Yang Z, He M, Yu M, Zhang B, Xie W, Wang H. (2019). Plasma 
indoleamine 2,3-dioxygenase activity as a potential biomarker for early diagnosis of multidrug-resistant 
tuberculosis in tuberculosis patients. Open Access Articles. https://doi.org/10.2147/IDR.S202369. 
Retrieved from https://escholarship.umassmed.edu/oapubs/3847 
Creative Commons License 
This work is licensed under a Creative Commons Attribution-Noncommercial 3.0 License 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Open Access Articles 
by an authorized administrator of eScholarship@UMMS. For more information, please contact 
Lisa.Palmer@umassmed.edu. 
OR I G I N A L R E S E A R C H
Plasma indoleamine 2,3-dioxygenase activity as
a potential biomarker for early diagnosis of
multidrug-resistant tuberculosis in tuberculosis
patients
This article was published in the following Dove Press journal:
Infection and Drug Resistance
Wen Shi1,*
Juan Wu1,*
Qi Tan1
Chun-Mei Hu2
Xia Zhang2
Hong-Qiu Pan3
Zhen Yang4
Meng-Yu He1
Min Yu1
Bo Zhang5
Wei-Ping Xie1
Hong Wang1
1Department of Respiratory and Critical
Care Medicine, Jiangsu Province Hospital.
The First Afﬁliated Hospital of Nanjing
Medical University, Nanjing, Jiangsu
Province, People’s Republic of China;
2Department of Tuberculosis, The Second
Hospital of Nanjing, Nanjing, Jiangsu
Province, People’s Republic of China;
3Department of Tuberculosis, The Third
Hospital of Zhenjiang City, Zhenjiang,
Jiangsu Province, People’s Republic of China;
4Department of Respiratory Medicine, Jiangbei
Hospital, Nanjing, Jiangsu Province, People’s
Republic of China; 5Department of Population
and Quantitative Health Sciences, University of
Massachusetts Medical School, Worcester, MA,
USA
*These authors contributed equally to this
work
Purpose: Multidrug-resistant tuberculosis (MDR-TB) remains a challenge of global TB
control, with difﬁculty in early detection of drug-sensitive tuberculosis (DS-TB). We inves-
tigate the diagnostic signiﬁcance of IDO as a potential biomarker to discriminate MDR
patients among the TB patients.
Patients and methods: Plasma indoleamine 2,3-dioxygenase (IDO) was measured by the
ratio of kynurenine (Kyn) to tryptophan (Trp) concentrations, using high performance liquid
chromatography-mass spectrometry (LC-MS/MS). Chest computed tomography (CT) ima-
ging signs from TB patients were collected and analyzed in 18 DS-TB patients, 16 MDR-TB
patients, 6 lung cancer (LC) patients, and 11 healthy individuals. Lung imaging signs from
TB patients were collected and analyzed.
Results: We found that plasma IDO activity was signiﬁcantly higher in the MDR-TB
patients than in the DS-TB patients (p=0.012) and in the LC patients (p=0.003). We
evaluated the diagnostic signiﬁcance of plasma IDO activity in discriminating the MDR-
TB group from the DS-TB group using a receiver operating characteristic (ROC) curve. With
a cutoff level of 46.58 uM/mM, the diagnostic sensitivity, speciﬁcity, positive predictive
value (PPV), and negative predictive value (NPV) for IDO activity were 87.50%, 72.22%,
73.68%, and 86.67%, respectively. Plasma IDO activity was higher in cavity cases than in
non-cavity cases (p=0.042), proving a positive correlation between lung cavity number and
cavity size (p<0.05, separately) among all the TB patients studied.
Conclusion: Our ﬁndings conﬁrmed that plasma IDO activity might have an auxiliary
diagnosis value for early discrimination of MDR-TB patients from DS-TB patients.
Among the TB patients with cavitary lung lesions, higher plasma IDO activity can indicate
a higher risk of MDR-TB.
Keywords: IDO, MDR-TB, LC-MS/MS, cavitary lung lesion
Introduction
Multidrug-resistant tuberculosis (MDR-TB) is a major threat to global tuberculosis
control.1 In 2017, there were 10 million new and relapse tuberculosis (TB) cases world-
wide; over 558,000 of these TB patients suffered fromMDR-TB, and only 25%ofMDR-
TB patients were notiﬁed.2 Missing people with MDR-TB, due to a failure of the local
healthcare system3 and lack of tools for diagnosis4 can lead to the systematic selection
and spread of MDR-TB strains. This increases the risk that we may lose control of TB in
Correspondence: Qi Tan; Wei-Ping Xie
Department of Respiratory and Critical
Care Medicine, Jiangsu Province Hospital,
The First Afﬁliated Hospital of Nanjing
Medical University, 300 Guangzhou Rd,
Nanjing 210029, Jiangsu Province, People’s
Republic of China
Tel +1 508 330 6097; +86 138 5150 6818
Email qi.tan@umassmed.edu;
wpxie@njmuedu.cn
Infection and Drug Resistance Dovepress
open access to scientiﬁc and medical research
Open Access Full Text Article
submit your manuscript | www.dovepress.com Infection and Drug Resistance 2019:12 1265–1276 1265
DovePress © 2019 Shi et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php
and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work
you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For
permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
http://doi.org/10.2147/IDR.S202369
 
In
fe
ct
io
n 
an
d 
Dr
ug
 R
es
ist
an
ce
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
14
6.
18
9.
22
8.
13
9 
on
 2
5-
Ju
n-
20
19
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
the future.5 In comparison with drug-sensitive tuberculosis
(DS-TB), MDR-TB treatments tend to use more toxic second-
line anti-TB drugs in combination, and in a prolonged treat-
ment regimen (the standard is 9–24 months for MDR-TB
versus 6 months for DS-TB)6 with less treatment efﬁciency,
potential patient incompliance and, unaffordably high treat-
ment costs.7,8 Clinical conﬁrmation of MDR-TB mostly
depends on identiﬁcation of Mycobacterium tuberculosis
(MTB) by smear or culture and determination of the strain
by drug-susceptibility testing (DST). However, this testing
usually takes longer than four weeks.9,10 More efﬁcient meth-
ods based on GeneXpert/RIF have been recommended by the
World Health Organization (WHO) for screening drug resis-
tant-TB.11 However, these methods are limited in early detec-
tion for MDR-TB due to inadequate sensitivity (46%), and
giving a false-positive result when few bacilli are present in
a clinical specimen (smear negative).12,13 Current determina-
tion of TB in immunology, pathology, and radiology cannot
discriminate drug-resistant TB from drug-sensitive TB.14,15
The lack of adequate tools is contributing to delayed detection
or even missed diagnoses of MDR-TB.16 As a result, these
missed cases can transmit the pathogen, and extend the MDR-
TB population in uncontrolled conditions.
Indoleamine 2,3-dioxygenase (IDO) is an intracellular,
non-secreted enzyme, and is a key rate-limiting enzyme
that catalyzes the catabolism of tryptophan (Trp) to kynur-
enine (Kyn).17,18 Induction of IDO in cells of the immune
system by IFN-γ is a technique that was developed in the
late 1980s.19,20 due to the anti-proliferative features of
IDO on bacteria, protozoa, and tumor cells.21 Numerous
studies in the past two decades have indicated that induced
IDO acts as a suppressive regulator in host immunity to
promote and prolong TB infection.12–26 In both animal
models and patient specimens, IDO was found to be
enriched in the inner layer of the granuloma22,23 and cap-
able of promoting long-term survival of the bacilli by
limiting the proliferation of CD4+T cells and
macrophages.27 Recent studies have demonstrated that
IDO activity in the serum, sputum, or pleura from pul-
monary TB (PTB) patients is increased, and can be an
independent predictor of mortality.24,26 Most of these stu-
dies were focused on TB patients; yet, these studies did
not distinguish whether the TB patients infected with drug-
sensitive or drug-resistant MTB strain. So, we still cannot
determine the role that IDO plays in MDR-TB infection.
Therefore, the differences in IDO activity in MDR-TB
patients compared to DS-TB patients have not yet been
adequately investigated.
In our previous work, MDR-TB patients—mostly with
more severe clinical symptoms and radiological lung
focuses—were recognized by an extreme drop of
CD4+T helper subset cell responses before treatment
which was markedly different from that in DS-TB cases,
including a more sharply decreased Th1 frequency, lower
IFN-γ concentration, and higher over-induced inﬂamma-
tory cytokine expressions in peripheral blood mononuclear
cells (PBMCs).28,29 Thus, we hypothesize that the increased
Trp and decreasing Kyn levels within IDO activity play
a crucial role. In this study, we investigate the diagnostic
signiﬁcance of IDO as a potential biomarker to discriminate
MDR patients from other TB patients. We also investigated
the IDO activity identiﬁcation signiﬁcance in MDR-TB
patients compared with lung cancer (LC) patients, and the
correlation of plasma IDO activity with the frequency and
size of cavitary lung lesions of TB patients.
Our ﬁndings indicated plasma IDO activity was a novel
biomarker for early diagnosis MDR-TB, and suggested
a potential target of host direct treatment (HDT) for MDR-
TB in future by indicating the crucial role of IDO in the
immune response against MDR-TB. Our ﬁndings con-
ﬁrmed that plasma IDO activity can remarkably discrimi-
nate MDR-TB patients from DS-TB patients, as well as
from lung cancer patients. Meanwhile we demonstrated
a higher plasma IDO activity in cavitary TB patients
than in non-cavitary TB patients. Plasma IDO activity
level was illustrated a positive correlation with the number
and size of lung cavitary lesions in patients with TB,
according to imaging signs. This hinted that plasma IDO
activity can also be a biomarker to boost imaging signs of
the cavity, indicating the risk of MDR-TB infection and
pathogen transmittance. In conclusion, our pilot investiga-
tion sheds light on plasma IDO activity performance in the
early identiﬁcation of MDR-TB patients, which may be an
auxiliary tool for promptly conducting the correct patients
into an isolation ward and thereby alleviating the spread of
MDR-TB.
Material and methods
Ethics statement
This study protocol was approved by the ethics committee of
the First Afﬁliated Hospital of Nanjing Medical University
(Jiangsu Province Hospital) and was performed adhering to
the ethical principles of the Declaration of Helsinki
(APPROVAL NUMBER/ID 2017-SRFA-163). All patients
provided written informed consent before enrollment.
Shi et al Dovepress
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Subjects and diagnostic criteria
From December 2017 to May 2018, 34 newly diagnosed
pulmonary TB patients, including 18 cases of DS-TB,
16 cases of MDR-TB, and 6 cases of LC, along with 11
HCs, were enrolled in the study and admitted to The
Public Health Medical Center of Nanjing City, Jiangbei
Hospital, Third Hospital of Zhenjiang City, and The First
Afﬁliated Hospital of Nanjing Medical University. All
participants were over 18 years old. All of the active
tuberculosis patients recruited were bacteriologically con-
ﬁrmed, and presented with a protracted cough, occasional
fever, blood-streaked phlegm or hemoptysis, night sweats,
fatigue, weight loss, and a positive chest computed tomo-
graphy (CT) with lung lesions and/or cavities. TB patients
with human immunodeﬁciency virus (HIV), cancer, auto-
immune diseases, liver and kidney diseases, undergoing
immunosuppressive treatment, blood system dysfunction,
or who were pregnant or lactating women were excluded.
DS-TB patients were conﬁrmed by a positive bacterial
culture with drug-sensitive stains and had no history of
TB. MDR-TB patients were diagnosed with a positive
sputum culture and baseline drug sensitivity tests using
at least two drugs—isoniazid and rifampin. LC patients
were diagnosed on the basis of detecting malignant cells in
a pulmonary biopsy. Our study contemporaneously
enrolled healthy controls (HCs) with normal chest
X-rays, no cough, fever, or weight loss, and no recent
exposure to TB.
Determination of radiological ﬁndings
Of the 34 pulmonary TB patients, chest CT scans showing
the lung lesions of 18 patients with DS-TB and 16 patients
with MDR-TB were collected before initial treatment regi-
men and reviewed in a random order by a medical group
of senior physicians in the department of respiratory med-
icine. The determination of the imaging signs included the
lung cavity prevalence, bilateral lungs, cavity number,
maximum cavity diameter, and sum diameters of all cav-
ities. Radiological ﬁndings on the chest CT scans of indi-
vidual patients were conﬁrmed by the physician’s decision.
Measurement of tryptophan and
kynurenine
Chemicals
L-Trp (Sigma-Aldrich, USA) and L-Kyn (Sigma-Aldrich,
USA) were dissolved in methanol and stored frozen at –
20℃. Methanol and formic acid (high-performance liquid
chromatography (HPLC) grade) were purchased from
Tedia (USA). Other organic solvents and chemicals were
all HPLC grade.
Analysis parameters of liquid
chromatography-tandem mass spectrometry
(LC-MS/MS)
The solvent and sample were separated by an auto sampler
(Agilent, USA) and a chromatographic pump (Agilent,
USA). The column was Reversal Phase-18 (RP-18) with
C18 protection pre-column. The column oven was set at
25 ℃. The mobile phase was methanol/water (95:5 v/v)
(water containing 0.1% formic acid), and the ﬂow rate of
the LC system was 200 µl/min. The analysis time for each
serum sample was four minutes.
The sample proﬁling analysis was performed by
a triple quadrupole mass spectrometer QTRAP®5000
(AbSciex, USA) with an ion source of electrospray ioniza-
tion (ESI); a detection method of positive ion detection;
a detection molecular weight of 209.1→145.9 (Kyn) and
205.3→149.0 (Trp); a scanning method of selection reac-
tion monitoring; a scanning time of 0.1 s; a scanning range
of 10–300 m/z (Kyn) and 10–300 m/z (Trp); and
a collision energy of 12.7 V (Kyn) and 22.3 V (Trp).
Sample and plasma pretreatment
The stock solutions of L-Kyn and L-Trp were further diluted
with methanol into a series of working solutions and stored
at –20℃, and were thawed at room temperature before LC/
MS analysis. The standard sample concentration ranges were
10–500 ng/ml (Kyn) and 12.5–400 ng/ml (Trp).
Ethylenediaminetetraacetic acid–anticoagulated plasma
samples were obtained according to the standard operating
procedure at the time of admission, and 100 µl of plasma
and 300 µl of methanol were added to a 1.5 ml centrifuge
tube. These were centrifuged at 12,000 rpm for 30 min at
4℃. Then, the supernatants were collected and stored at –
80℃. After this, the mixture was acutely vortexed for 10 s
and centrifuged at 12,000 rpm for 5 min at 4 ℃, then the
supernatant was transferred to the auto sampler. The injec-
tion volume of every sample was 10 µl for LC-MS/MS.
The plasma IDO activity was estimated by the plasma
ratio of the Kyn concentration to the Trp concentration.
Statistical analysis
Summary statistics were shown for the continuous mea-
surements with their means and standard deviations (SDs),
and for the categorical measurements with their
Dovepress Shi et al
Infection and Drug Resistance 2019:12 submit your manuscript | www.dovepress.com
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frequencies and percentages. Logarithmic transformations
were performed for the Kyn concentrations and IDO activ-
ities to avoid the inﬂuence of non-normality. Transformed
Kyn concentrations and IDO activities were adopted in the
statistical analysis. A Student t-test was used to compare
each of the two groups. A one-way analysis of variance
(ANOVA) test with the least signiﬁcant differences (LDSs)
post-hoc test was used for multiple-group comparison.
Categorical data were analyzed using Fisher’s exact tests.
The Mann-Whitney test was used for nonparametric
unpaired groups. The diagnostic signiﬁcance of the IDO
activity in discriminating the MDR-TB patients from the
DS-TB and LC patients was evaluated by an area under
the receiver operating characteristic (ROC) curve (AUC),
sensitivity, speciﬁcity, positive predictive value (PPV), and
negative predictive value (NPV). Spearman’s t-test was
used to detect the correlation between the Try-Kyn path-
way and radiological ﬁndings. Data analysis were per-
formed using SPSS software (SPSS 25.0, Chicago, IL,
USA), and a signiﬁcance level of 0.05 was considered in
the hypothesis testing.
Results
Demographics and clinical parameters
A total of 51 participants were included, with 11 HCs,
18 DS-TB cases, 16 MDR-TB cases, and 6 LC cases (3
lung adenocarcinoma cases, 2 squamous cell lung can-
cer cases, and 1 small cell lung cancer case). The
baseline demographic characteristics of the study par-
ticipants are summarized in Table 1. There was no
difference among groups in the distribution of age,
gender, body mass index (BMI), or smoking status.
Meanwhile, radiological ﬁndings of the DS-TB and
the MDR-TB patients are summarized in Table 2.
A higher proportion of the MDR-TB patients
demonstrated cavitary lung lesions compared to the
DS-TB patients. No difference of bilateral lung lesion
prevalence between the DS-TB patients and the MDR-
TB patients was found. Figure 1 shows the imaging
signs of the DS-TB (Figure 1A and B) and MDR-TB
patients (Figure 1C and D).
Plasma concentrations of Kyn, Trp, and
IDO activity in the four study groups
As shown in Figure 2A, the Kyn concentration in plasma
was signiﬁcantly higher in patients with MDR-TB than in
the HC, DS-TB, and LC groups (988.26±332.75 nM vs
757.33±160.98 nM, p=0.013; 988.26±332.75 nM vs
743.50±145.42 nM, p=0.003; 988.26±332.75 nM vs
725.79±103.42 nM, p=0.022), whereas no signiﬁcant dif-
ference was found between the HC and DS-TB groups
(757.33±160.98 nM vs 743.50±145.42 nM, p=0.844)
(Figure 2A). Compared with MDR-TB patients, the HC,
DS-TB, and LC patients had a signiﬁcantly higher Trp
concentration (23.21±5.35 µM vs 12.19±3.79 µM,
p<0.0001; 19.05±6.11 µM vs 12.19±3.79 µM, p<0.0001;
21.27±5.65 µM vs 12.19±3.79 µM, p=0.001) (Figure 2B).
In addition, we also observed a decreasing trend in the
plasma Trp concentration in the DS-TB group compared
with the HC group, with the difference being signiﬁcant
(19.05±6.11 µM vs 23.21±5.35 µM, p=0.044). As a result,
our data revealed signiﬁcantly higher IDO activity (Kyn/
Trp ratio) in the MDR-TB individuals than in the HC, DS-
TB, and LC groups (90.61±49.09 µM/mM vs 35.18
±13.92 µM/mM, p=0.003; 90.61±49.09 µM/mM vs 43.84
±19.53 µM/mM, p=0.012; 90.61±49.09 µM/mM vs 35.91
±9.56 µM/mM, p=0.003), whereas no signiﬁcant differ-
ence was found between the HC and DS-TB groups (35.18
±13.92 µM/mM vs 43.84±19.53 µM/mM, p=0.687)
(Figure 2C).
Table 1 Baseline characteristics of the participants in the four groups
Variable HC
(n=11)
DS-TB
(n=18)
MDR-TB
(n=16)
LC
(n=6)
p-value
Age (years) 51.09±10.77 48.72±15.97 58.00±6.67 60.50±3.73 0.053a
Gender (male/female) 8/3 14/4 13/3 5/1 0.946b
BMI (kg/m2) 21.11±1.40 20.56±3.24 20.73±2.20 22.48±2.54 0.437a
Smoking (no/yes) 8/3 7/11 6/10 1/5 0.113b
Type of clinical TB Non-TB Pulmonary TB Non-TB
Notes: aOne-way analysis of variance (ANOVA) test was used for the multiple-group comparison. bFisher exact test was used for categorical data. Data are shown as mean
± SD or ratios.
Abbreviations: HC, healthy control; DS-TB, drug-sensitive tuberculosis; MDR-TB, multidrug-resistant tuberculosis; LC, lung cancer; BMI, body mass index.
Shi et al Dovepress
submit your manuscript | www.dovepress.com
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Diagnostic signiﬁcance of plasma
concentrations of Kyn, Trp, and IDO
activity for discriminating MDR-TB
patients from TB patients
To evaluate the potential values of the plasma tryptophan-
kynurenine pathway for the diagnosis of MDR-TB, three
ROC curves were plotted (Figure 3). Using optimal cut-off
points, the diagnostic ability of these parameters is shown in
Table 3. At a cutoff of 46.58 µM/mM, IDO activity had
a sensitivity of 87.50%, a speciﬁcity of 72.22%, a PPV of
73.68%, and an NPV of 86.67% (AUC =0.882, Figure 3C,
Table 3).We also analyzed the diagnostic value of plasmaKyn
concentration and Trp concentration, and the two key indica-
tors of the plasma tryptophan-kynurenine pathway can distin-
guishMDR-TB groups as well (Kyn, AUC =0.764; Trp, AUC
=0.833, Figure 3A and B, Table 3). In the analysis, plasma
IDO activity had a higher AUC thanKyn or Trp concentration.
Table 2 Radiological characteristics of the DS-TB and MDR-TB patients
Radiological ﬁndings DS-TB
(n=18)
MDR-TB
(n=16)
p-value
Cavity prevalence [n(%)] 6 (33.33%) 13 (81.25%) 0.007* a
Cavity number (n) 0.50±0.79 2.44±2.25 0.001* b
Bilateral lung lesions [n(%)] 2 (11.11%) 5 (31.25%) 0.214c
Maximum diameter of cavity (mm) 8.33±13.39 22.19±18.79 0.012* b
Sum of cavity diameters (mm) 10.56±16.97 34.38±29.26 0.006* b
Notes: *Represents p-value less than 0.05. aFisher exact test was used for categorical data. Comparison of proportions of patients with lung cavities between the DS-TB
group and MDR-TB group.bMann-Whitney test was used for nonparametric unpaired groups. cFisher exact test was used for categorical data. Comparison of proportions of
patients with bilateral lung lesions between the DS-TB group and MDR-TB group. Data are shown as mean ± SD or percentages.
Abbreviations: DS-TB, drug-sensitive tuberculosis; MDR-TB, multidrug-resistant tuberculosis.
A B
C D
Figure 1 Imaging signs of transvers CT scans from patients in the drug-sensitive tuberculosis (DS-TB) group and multidrug-resistant tuberculosis (MDR-TB) group. (A) Lung
window of chest CT scan from a patient in the MDR-TB group in the present study, showing multiple large cavities (arrows), mainly in the left upper lobe, with lung volume
loss. (B) Lung window of chest CT scan from another patient in the MDR-TB group in the present study, showing extensive cavitary lesions (arrows) evolved in the bilateral
lungs. (C) Lung window of chest CT scan from a patient in the DS-TB group in the present study, showing at the level of the left basal trunk small nodules branching in the
linear and lobular area of bronchiectasis (arrows), with a single cavity formation in the left lower lobe. (D) Lung window of chest CT scan from another patient in the DS-TB
group in the present study, showing at the level of the aortic arch nodular opacities and consolidations (arrow), and the lobular area of inﬁltration lesions.
Dovepress Shi et al
Infection and Drug Resistance 2019:12 submit your manuscript | www.dovepress.com
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Figure 2 Boxlots of plasma concentrations of Kyn, Trp, and IDO activity in HCs and patients with DS-TB, MDR-TB, and LC. (A) The Kyn concentration in the
MDR-TB group was higher than in the HC, DS-TB, and LC groups (MDR-TB vs HC, p=0.013; MDR-TB vs DS-TB, p=0.003; MDR-TB vs LC, p=0.022). Meanwhile,
no signiﬁcant difference was found between the HC and DS-TB groups (p=0.844). (B) The Trp concentration in the MDR-TB group was lower than in the HC, DS-
TB, and LC groups (MDR-TB vs HC, p<0.0001; MDR-TB vs DS-TB, p<0.0001; MDR-TB vs LC, p=0.001). In addition, the Trp concentration in the DS-TB group
was lower than in the HCs (p=0.044). (C) The IDO activity (Kyn/Trp ratio) in patients with MDR-TB was higher than in the HC, DS-TB, and LC groups (MDR-TB
vs HC, p=0.003; MDR-TB vs DS-TB, p=0.012; MDR-TB vs LC, p=0.003). Meanwhile, no signiﬁcant difference was found between the HC and DS-TB groups
(p=0.687).
Abbreviations: Kyn, kynurenine; Trp, tryptophan; IDO, indoleamine 2,3-dioxygenase; HC, healthy control; DS-TB, drug-sensitive tuberculosis; MDR-TB, multidrug-
resistant tuberculosis; LC, lung cancer.
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Figure 3 ROC curves of plasma concentrations of Kyn, Trp, and IDO activity for discriminating MDR-TB patients from DS-TB patients. (A) Using a cutoff of 857.5 nM,
plasma Kyn concentration had a diagnostic sensitivity of 68.75% and a speciﬁcity of 88.89% (AUC =0.764). (B) The AUC was 0.833 for Trp concentration (cutoff value 17.58
µM/mM, sensitivity 93.75%, speciﬁcity 72.22%). (C) The AUC of IDO activity in differentiating patients with MDR-TB from DS-TB was 0.882, and the cutoff value was 46.58
µM/mM. Sensitivity and speciﬁcity were 87.50% and 72.22%, respectively.
Abbreviations: Kyn, kynurenine; Trp, tryptophan; IDO, indoleamine 2,3-dioxygenase; AUC, area under the curve; ROC, receiver operating characteristic; MDR-TB,
multidrug-resistant tuberculosis; DS-TB, drug-sensitive tuberculosis.
Table 3 Diagnostic signiﬁcance of plasma concentrations of Kyn, Trp, and IDO activity for discriminating MDR-TB patients from TB
patients
Variable AUC Cutoff Sensitivity Speciﬁcity PPV NPV
DS-TB vs MDR-TB
Kyn 0.764 857.5 nM 68.75% 88.89% 84.62% 76.19%
Trp 0.833 17.58 µM 93.75% 72.22% 75.00% 92.86%
IDO activity 0.882 46.58 µM/mM 87.50% 72.22% 73.68% 86.67%
Note: *Represents a p-value less than 0.05.
Abbreviations: AUC, area under the curve; PPV, positive predictive value; NPV, negative predictive value; DS-TB, drug-sensitive tuberculosis; MDR-TB, multidrug-resistant
tuberculosis; Kyn, kynurenine; Trp, tryptophan; IDO, indoleamine 2,3-dioxygenase.
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Association of plasma concentrations of
Kyn, Trp, and IDO activity with
radiological ﬁndings
In addition, we explored the Spearman correlation analysis of
the three plasma indexes with radiological ﬁndings in the TB
(DS-TB, MDR-TB) patients. As presented in Table 4, Trp
concentration was negatively correlated with cavity number,
the maximum diameter of the cavity, and the sum of cavity
diameters (r = –0.373, p=0.030; r = –0.386, p=0.024;
r = –0.408, p=0.017). IDO activity showed a positive associa-
tion with the maximum diameter of the cavity, and the sum of
cavity diameters (r =0.441, p=0.009; r =0.383, p=0.026;
r =0.410, p=0.016). Subsequently, subgroup analyses were
carried out and no signiﬁcant differenceswere found in theDS-
TB and MDR-TB patients separately.
Plasma concentrations of Kyn, Trp, and
IDO activity in cavitary and non-cavitary
pulmonary TB patients
Next, we investigated plasma tryptophan-kynurenine path-
way indexes in non-cavitary pulmonary TB patients
(n=15) and cavitary pulmonary TB patients (n=19) on
CT scanning. No signiﬁcant difference was found in Kyn
concentration between the two subgroups, but there was
a higher trend in patients with cavities (911.09±336.75 nM
vs 792.30±162.21 nM, p=0.296) (Figure 4A). Compared
with non-cavitary TB patients, cavitary patients had sig-
niﬁcantly lower Trp concentrations (13.88±5.21 µM vs
18.28±6.55 µM, p=0.037) (Figure 4B) and higher IDO
activity (79.03±50.71 µM/mM vs 49.15±23.00 µM/mM,
p=0.042) (Figure 4C).
Diagnostic value of plasma concentrations
of Kyn, Trp, and IDO activity for
discriminating LC and MDR-TB patients
Finally, based on ROC curves, we evaluated the diagnostic
signiﬁcance of plasma tryptophan-kynurenine pathway
indexes for distinguishing MDR-TB from other lung dis-
eases (LC). With an optimal calculated IDO activity thresh-
old of 49.23 µM/mM, the AUC was 0.958, with a sensitivity
and speciﬁcity of 87.50% and 100.00%, respectively, and
with a PPV and NPVof 100.00% and 75.00%, respectively
2400
Kyn concentrationA B C
(nM) (µM)
p=0.296 p=0.037
p=0.042
(µM/mM)
Trp concentration IDO activity
40 240
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Figure 4 Boxplots of plasma concentrations of Kyn, Trp, and IDO activity in non-cavitary and cavitary TB patients. (A) There was no difference in Kyn concentration
between the two groups (p=0.296). (B) The Trp concentration in cavitary TB patients was lower than in non-cavitary TB patients (p=0.037). (C) The IDO activity in cavitary
TB patients was higher than in non-cavitary TB patients (p=0.042).
Abbreviations: Kyn, kynurenine; Trp, tryptophan; IDO, indoleamine 2,3-dioxygenase; TB, tuberculosis.
Table 4 Correlation coefﬁcient between cavity number, maximum cavity diameter, sum of cavity diameters, and kynurenine,
tryptophan, and IDO activity by patient group
Kyn Trp IDO activity Kyn Trp IDO activity Kyn Trp IDO activity
TB (DS, MDR) patients DS–TB patients MDR–TB patients
Cavity number(r) 0.301 –0.373 0.441 –0.245 –0.033 –0.134 0.451 –0.128 0.331
p-value 0.084 0.030* 0.009* 0.328 0.895 0.597 0.08 0.636 0.210
Maximum cavity diameter (r) 0.141 –0.386 0.383 –0.228 –0.068 –0.085 0.104 –0.317 0.324
p–value 0.427 0.024* 0.026* 0.363 0.790 0.738 0.701 0.232 0.220
Sum of cavity diameters(r) 0.183 –0.408 0.410 –0.235 –0.062 –0.095 0.245 –0.393 0.435
p-value 0.301 0.017* 0.016* 0.347 0.807 0.707 0.36 0.132 0.093
Notes: *Represents p-value less than 0.05. Data are shown as correlation coefﬁcient (r); r and p-value by Spearman rank correlation.
Abbreviations: Kyn, kynurenine; Trp, tryptophan; IDO, indoleamine 2,3-dioxygenase.
Dovepress Shi et al
Infection and Drug Resistance 2019:12 submit your manuscript | www.dovepress.com
DovePress
1271
 
In
fe
ct
io
n 
an
d 
Dr
ug
 R
es
ist
an
ce
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
14
6.
18
9.
22
8.
13
9 
on
 2
5-
Ju
n-
20
19
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
(Figure 5C, Table 5). The AUCs of Kyn and Trp were 0.802
and 0.917, respectively (Figure 5A and B, Table 5).
Discussion
Despite increased research activity in tuberculosis, clinicians
remain hindered by gaps in knowledge and understanding of
both pathogenesis and the host factors that contribute to the
susceptibility of MDR-TB disease.30,31 We are clearly lack-
ing host directed biomarkers for indicating disease status,
especially in the early stage of MDR-TB.32 To date, few
studies have discussed IDO activity in MDR-TB patients,
either to clearly determine its proﬁle in host immunity against
MDR-TB or in lung lesions from MDR-TB patients.
It has been recognized that tryptophan metabolism
brings twofold consequences. First, starving the bacteria
by depleting the local microenvironment of tryptophan,
which is essential for most pathogen metabolism.33,34
Second, inducing the apoptosis of host immune cells, 35,36
mostly lymphocytes activated by tryptophan downstream
catabolites, including kynurenine and 3-hydroxyanthranilic
acid (3-HAA). IDO activity is evolved in suppressing
CD4+T cell proliferation.37 inducing antigen-presenting
cells (APC).38 and promoting the differentiation of
CD4+CD25+Foxp3+regulatory T cells (Treg) cells from
naive CD4+ T cells.37,39,40 Therefore, IDO activity is
believed to contribute to mycobacteria burden increase
and persistence in chronic infection. The present study
shows that IDO activity in the MDR-TB group was higher
than in the DS-TB group, and IDO activity was also asso-
ciated with lung cavitary lesions in the patients with TB.
This is consistent with our previous ﬁnding that MDR-TB
patients show lower CD4+IFN-γ+T cell response and over-
induced Treg activation in PBMCs along with more severe
clinical symptoms and lung lesions.28,29,41
Abundant evidence also indicates IDO activity not only
participates in the pathogenesis of TB, but also can be
a complementary tool for diagnosis and prognosis of
TB.23–26,42 However, no studies have been conducted to
evaluate its diagnostic signiﬁcance in MDR-TB patients.
In this regard, we clearly showed that serum IDO activity
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Figure 5 ROC curves of plasma concentrations of Kyn, Trp, and IDO activity for discriminating LC and MDR-TB patients. (A) The AUC of Kyn concentration was 0.802,
with a sensitivity and speciﬁcity of 68.75% and 83.33%, respectively. (B) The sensitivity and speciﬁcity of the Trp concentration were found to be 93.75% and 83.33%,
respectively, with an AUC of 0.917, and a cut-off value of 17.98 µM was obtained. (C) The sensitivity and speciﬁcity for plasma IDO activity were found to be 87.50% and
100.00%, respectively (AUC =0.958).
Abbreviations: Kyn, kynurenine; Trp, tryptophan; IDO, indoleamine 2,3-dioxygenase; MDR-TB, multidrug-resistant tuberculosis; DS-TB, drug-sensitive tuberculosis.
Table 5 Diagnostic signiﬁcance of plasma concentrations of Kyn, Trp, and IDO activity for discriminating MDR-TB patients from the
LC patients
Variable AUC Cutoff Sensitivity Speciﬁcity PPV NPV
LC vs MDR-TB
Kyn 0.802 852.7 nM 68.75% 83.33% 91.67% 50.00%
Trp 0.917 17.98 µM 93.75% 83.33% 93.75% 83.33%
IDO activity 0.958 49.23 87.50% 100.00% 100.00% 75.00%
Note: *Represents p-values less than 0.05.
Abbreviations: AUC, area under the curve; PPV, positive predictive value; NPV, negative predictive value; MDR-TB, multidrug-resistant tuberculosis; Kyn, kynurenine; Trp,
tryptophan; IDO, indoleamine 2,3-dioxygenase; LC, lung cancer.
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in MDR-TB discriminates this condition from DS-TB
groups, with a cutoff level of 46.58 µM/mM, sensitivity
87.50%, speciﬁcity 72.22%, and positive predictive value
(PPV) of 73.68%. We also measured plasma Kyn and Trp
concentration as some of the IDO metabolic pathway
products in MDR-TB patients and consistently found sig-
niﬁcant differentiations in MDR-TB patients from DS-TB
patients. A study in Japan reported in 2011 enrolled 174
consecutive patients and showed that serum IDO activity
was an independent predictor of mortality.24 A prospective
clinical study for TB patients with HIV infection demon-
strated that, compared to the higher IDO activity before
diagnosis, IDO activity decreased after anti-TB
treatment.42 A large-scale study will be conducted in
future with a well-designed protocol to validate this
ﬁnding.
In the present study, the IDO activity showed
a signiﬁcant positive correlation with lung cavity preva-
lence and lung cavity size. We also observed the associa-
tion of the three plasma indexes with radiological ﬁndings
in DS-TB and MDR-TB patients separately, and no sig-
niﬁcant differences were found. We further found IDO
activity was relatively higher in 19 patients with pulmon-
ary cavities, compared with 15 patients who presented
with non-cavities on computed tomography (CT) scan-
ning. Based on accumulating evidence from studies on
animal and human specimens, M. tuberculosis infection
is associated with high expression of IDO in the infected
phagocytes in the center structure of the granuloma, pre-
venting T cell protection and thereby further promoting
bacterial survival, which leads to cavitary lesions and
disease transmission.22,23 High bacillary titers in cavities
increase the probability of establishing drug-resistant bac-
terial populations.43,44 Along with imaging ﬁndings, it is
therefore understandable that thicker walls and larger cav-
ities are more likely to be associated with MDR-TB and
extensively drug-resistant tuberculosis (XDR-TB).45,46
While MDR-TBs tend to be more extensive in chest CT
imaging than DS-TBs,47 imaging signs still cannot inde-
pendently discriminate MDR-TB from DS-TB.45,48 Our
ﬁndings imply that higher plasma IDO activity indicates
more severe MTB destruction in the lung parenchymal of
patients, related to more extensive cavity lung lesions
(cavity prevalence and cavity size), leading to
a considerably higher risk of MDR-TB developing and
greater transmission of the pathogen.49,50 Although ima-
ging data from more cases is needed to conﬁrm our pilot
evaluation in this study, IDO activity may be a feasible
tool along with CT imaging for early identiﬁcation of such
patients. This is urgently needed to facilitate promptly
conducting the correct TB patients into an isolation ward,
thereby alleviating the spread of MDR-TB.
We found signiﬁcantly higher plasma IDO activity in
the MDR-TB group than in the lung cancer group, with
a discriminating signiﬁcance. Several studies have shown
that an increase in IDO activity is associated with poor
prognosis in cancer patients.51 In our study, due to the
limitation of a small sample size of lung cancer cases
with no small cell lung cancer (NSCLC) cases or small
cell lung cancer (SCLC) cases, plasma IDO activity
showed no statistical discrimination from HCs. Given the
current absence of efﬁcient biomarkers to distinguish
MDR-TB from lung cancer (and vice versa), 52 we call
for more feasible and powerful tools for identiﬁcation of
these two diseases. There is overlap between pulmonary
tuberculosis and malignant lesions. Using high radioden-
sities on enhanced CT, MRI or18 F-FDG PET/CT is
a sensitive tool for identifying lung cancer53,54 however
especially in MDR-TB patients parenchymal consolida-
tions and scarring with parenchymal and cavitary nodal
calciﬁcations are more common and poorly deﬁned, and
patchy in reactivated disease,55–57 all of which could also
be consistent with a lung cancer and thus leading to
unnecessary invasive tissue collection and resections in
these populations.58 An earlier study reported by Seo KJ
et al upon analyzing clinical specimens from TB patients,
demonstrated that is was possible to use IDO as an immu-
nohistochemical marker to differentiate between tubercu-
lous granuloma (TG) and non-tuberculousgranuloma
(NG).23 However, the limitations of this method are the
invasive procedures required to obtain the pathologic spe-
cimens, and the longer duration required for histopathol-
ogy measurement. IDO’s expression in tuberculous
granuloma of a nonhuman primate model was found to
increase and to be associated with host–Mycobacterium
tuberculosis interactions, which either result in acute infec-
tion or the control of infection in a latent state.23,40
However, we are still uncertain about increasing plasma
IDO activity in human extrapulmonary tuberculosis or
latent tuberculosis because of the difﬁculty in collecting
human samples with variable confounding factors.40 We
assumed that plasma IDO activity in human latent TB or
extrapulmonary TB might be increasing but be lower than
in human MDR-TB. This assumption will be validated in
future study. Recently, another study on serum markers
found than the evaluation of circulating cell-free DNA
Dovepress Shi et al
Infection and Drug Resistance 2019:12 submit your manuscript | www.dovepress.com
DovePress
1273
 
In
fe
ct
io
n 
an
d 
Dr
ug
 R
es
ist
an
ce
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
14
6.
18
9.
22
8.
13
9 
on
 2
5-
Ju
n-
20
19
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
(ccfDNA) is more sensitive and speciﬁc than carcinoem-
bryonic antigen (CEA), carbohydrate antigen 125
(CA125), and neuron-speciﬁc enolase (NSE) in differen-
tiating NSCLC from tuberculosis.59 Unfortunately, these
approaches are currently costly, with a low throughput.
Therefore, our data from a small group of NSCLC
patients, while requiring conﬁrmation in future studies
with a larger cohort, shed light on the value of plasma
IDO activity, which seems to be potentially feasible as
a compensatory tool for imaging or histopathology identi-
ﬁcation of MDR-TB from among other lung malignant
diseases. Our pilot study used IDO activity as an auxiliary
biomarker to discriminate MDR-TB from DS-TB and lung
cancer, which can contribute to developing a combined
diagnostic procedure with other biomarkers. For instance,
in Chao Liu et al.’s reporting, the panel containing
Programmed cell death protein 1 (PD-1), interleukin-10
(IL-10), Interleukin-2 receptor alpha (IL-2Rα) and cancer
antigen 15-3 (CA15-3) as biomarkers discriminated breast
cancer from benign breast disease with high efﬁciency.60
Several limitations exist in this study. The sample cases
were selected within the restrictions of distance, transport
duration, and parallel period (2 h) for blood drawing to
keep the temperature and biological metabolism conditions
of the body consistent (the present cases were all from east
China). Thus, future studies should be performed with
more cases of MDR-TB from different regions, along
with other pulmonary infections and more malignant cavi-
tary lung disease cases as controls to determine if increas-
ing of IDO activity is speciﬁc to MDR-TB. Second, we
examined IDO activity, determined by the plasma Kyn/Trp
ratio, but lacked molecular or pathological conﬁrmation of
IDO expression in these patients. Origin of increased IDO
activity in the plasma of MDR-TB patients in this study is
still not clear in terms of clarifying the mechanisms in
MDR-TB. Previous studies have focused mostly on TB
conditions, with uncertainty around MDR-TB. Future stu-
dies will be required to clarify these issues. Third, further
studies evaluating MDR-TB patients from baseline to after
a standard treatment regimen, at different time points,
should be performed to conﬁrm that IDO activity could
be used to assist diagnosis of MDR-TB and to monitor
anti-TB therapy.
Conclusion
IDO activity in MDR-TB patients was predominantly
higher than that in DS-TB patients and HCs, with the
diagnostic signiﬁcance in discriminating from the DS-
TB group and lung cancer group. We found that IDO
activity was positively correlated with cavitary lung
lesions in patients with TB, potentially indicating
a more severe infectious condition and higher risk of
developing MDR-TB. We conducted this study to pro-
pose and test plasma IDO activity as a novel biomarker
candidate for the early detection of MDR-TB from DS-
TB. Our ﬁnding suggested that plasma IDO activity can
be used as a potential biomarker to assist chest CT scans
in the early detection of MDR-TB. However, this study
is only a pilot study, and a large-scale study is needed to
conﬁrm our ﬁndings. This pilot study allows a better
understanding of IDO’s participation in the pathogenesis
of MDR- TB and DS – TB, and can contribute to
developing a combined diagnostic procedure with other
biomarkers.
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